Assessing and managing frailty in advanced heart failure: An International Society for Heart and Lung Transplantation consensus statement

The Journal of Heart and Lung Transplantation, Journal Year: 2023, Volume and Issue: 43(1), P. 1 - 27

Published: Dec. 15, 2023

Language: Английский

---

6PPD induced cardiac dysfunction in zebrafish associated with mitochondrial damage and inhibition of autophagy processes

Journal of Hazardous Materials, Journal Year: 2024, Volume and Issue: 471, P. 134357 - 134357

Published: April 21, 2024

Language: Английский

---

Mechanical stress induced mitochondrial dysfunction in cardiovascular diseases: Novel mechanisms and therapeutic targets

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 174, P. 116545 - 116545

Published: April 10, 2024

Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide. Others and our studies have shown that mechanical stresses (forces) including shear stress cyclic stretch, occur in various pathological conditions, play significant roles development progression CVDs. Mitochondria regulate physiological processes cardiac vascular cells mainly through adenosine triphosphate (ATP) production, calcium flux redox control while promote cell death electron transport complex (ETC) related cellular response. Mounting evidence reveal stress-induced mitochondrial dysfunction plays a vital role pathogenesis many CVDs heart failure atherosclerosis. This review summarized functions cardiovascular system under (graphical abstract). The study can further understanding underlying mechanisms, identify potential therapeutic targets, aid novel treatments

Language: Английский

---

Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium–Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(5), P. 2484 - 2484

Published: Feb. 20, 2024

Different multifactorial pathophysiological processes are involved in the development of heart failure (HF), including neurohormonal dysfunction, hypertrophy cardiomyocytes, interstitial fibrosis, microvascular endothelial inflammation, pro-thrombotic states, oxidative stress, decreased nitric oxide (NO) bioavailability, energetic epicardial coronary artery lesions, rarefaction and, finally, cardiac remodeling. While different pharmacological strategies have shown significant cardiovascular benefits HF with reduced ejection fraction (HFrEF), there is a residual unmet need to fill gap terms knowledge mechanisms and efficacy outcomes agents preserved (HFpEF). Recently, type-2 sodium–glucose transporter inhibitors (SGLT2i) been contribute reduction composite outcome hospitalizations mortality across entire spectrum fraction. Moreover, glucagon-like peptide-1 receptor agonists (GLP1-RA) demonstrated patients high risk, excess body weight or obesity HF, particular HFpEF. In this review, we will discuss biological pathways potentially action SGLT2i GLP1-RA, which may explain their effective roles treatment as well potential implications use these agents, also combination therapies clinical practice.

Language: Английский

---

Heart Failure With Preserved Ejection Fraction in the Elderly Population: Basic Mechanisms and Clinical Considerations

Canadian Journal of Cardiology, Journal Year: 2024, Volume and Issue: 40(8), P. 1424 - 1444

Published: April 10, 2024

---